MSJ917925_supplemental_figure_1 – Supplemental material for Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri® Observational Program (TOP)

Supplemental material, MSJ917925_supplemental_figure_1 for Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri® Observational Program (TOP) by Helmut Butzkueven, Maria Trojano, Ludwig Kappos, Tim Spelman, Heinz Wiendl, Karen Rosales, Ray Su, Stephanie Licata, Pei-Ran Ho and Nolan Campbell in Multiple Sclerosis Journal